Cabenuva Kit
Product Images NDC 49702-253

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 50 technical images submitted to the FDA as part of the official labeling for Cabenuva (NDC 49702-253). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viiv Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Cabotegravir Chemical Structure (Cabenuva Spl Graphic 01)

FDA Label Image

Rilpivirine Chemical Structure (Cabenuva Spl Graphic 02)

FDA Label Image

Cabenuva Instructions For Use 400mg_600mg Kit (Cabenuva Spl Graphic 03)

Cabenuva Instructions For Use 400mg_600mg Kit (Cabenuva Spl Graphic 03)
These are the instructions for administering CABENUVA, which is a combination of Cabotegravir and Rilpivirine. It is an injectable suspension used only for gluteal intramuscular use. These instructions are intended for healthcare professionals only.*
FDA Label Image

Contents Of Kit (Cabenuva Spl Graphic 04)

FDA Label Image

Figure A (Cabenuva Spl Graphic 05)

Figure A (Cabenuva Spl Graphic 05)
This text implies a suggestion to conduct a routine check of the expiration date of medicine. It is advisable to regularly monitor the expiration date of medicines in order to ensure their efficacy and safety.*
FDA Label Image

Figure B (Cabenuva Spl Graphic 06)

FDA Label Image

Figure C (Cabenuva Spl Graphic 07)

FDA Label Image

Figure D (Cabenuva Spl Graphic 08)

FDA Label Image

Figure E (Cabenuva Spl Graphic 09)

FDA Label Image

Figure F (Cabenuva Spl Graphic 10)

FDA Label Image

Figure G (Cabenuva Spl Graphic 11)

FDA Label Image

Figure H (Cabenuva Spl Graphic 12)

FDA Label Image

Figure I (Cabenuva Spl Graphic 13)

FDA Label Image

Figure J (Cabenuva Spl Graphic 14)

FDA Label Image

Figure K (Cabenuva Spl Graphic 15)

FDA Label Image

Figure L (Cabenuva Spl Graphic 16)

FDA Label Image

Figure M (Cabenuva Spl Graphic 17)

FDA Label Image

Figure N (Cabenuva Spl Graphic 18)

FDA Label Image

Figure O (Cabenuva Spl Graphic 19)

FDA Label Image

Figure P (Cabenuva Spl Graphic 20)

FDA Label Image

Figure Q (Cabenuva Spl Graphic 21)

FDA Label Image

Figure R (Cabenuva Spl Graphic 22)

FDA Label Image

Figure S (Cabenuva Spl Graphic 23)

FDA Label Image

Figure T (Cabenuva Spl Graphic 24)

Figure T (Cabenuva Spl Graphic 24)
This text is not enough to provide a useful description of anything. It only mentions "Sharps disposal container" which could refer to various types of containers used for disposing of medical needles or other sharps. More context or information is needed.*
FDA Label Image

Figure U (Cabenuva Spl Graphic 25)

FDA Label Image

Cabenuva Instructions For Use 600mg_900mg Kit (Cabenuva Spl Graphic 26)

Cabenuva Instructions For Use 600mg_900mg Kit (Cabenuva Spl Graphic 26)
The text appears to be instructions for use of CABENUVA, which is a combination of Cabotegravir and Rilpivirine, administered as extended-release injectable suspension for gluteal intramuscular use only. It is meant for healthcare professionals' administration only.*
FDA Label Image

Contents Of Kit (Cabenuva Spl Graphic 27)

Contents Of Kit (Cabenuva Spl Graphic 27)
The text provides a list of items related to injections, including cabotegravir and rilpivirine vials, vial adapters and caps, rubber stoppers, syringes, syringe labels, injection needles, and needle caps. It can be useful for medical professionals who need to administer injections.*
FDA Label Image

Figure A (Cabenuva Spl Graphic 28)

Figure A (Cabenuva Spl Graphic 28)
The given text is a brief instruction that advises the reader to check the expiration date of their medicine. No further information on the context or purpose is provided.*
FDA Label Image

Figure B (Cabenuva Spl Graphic 29)

FDA Label Image

Figure C (Cabenuva Spl Graphic 30)

FDA Label Image

Figure D (Cabenuva Spl Graphic 31)

FDA Label Image

Figure E (Cabenuva Spl Graphic 32)

FDA Label Image

Figure F (Cabenuva Spl Graphic 33)

FDA Label Image

Figure G (Cabenuva Spl Graphic 34)

FDA Label Image

Figure H (Cabenuva Spl Graphic 35)

FDA Label Image

Figure I (Cabenuva Spl Graphic 36)

FDA Label Image

Figure J (Cabenuva Spl Graphic 37)

FDA Label Image

Figure K (Cabenuva Spl Graphic 38)

FDA Label Image

Figure L (Cabenuva Spl Graphic 39)

FDA Label Image

Figure M (Cabenuva Spl Graphic 40)

FDA Label Image

Figure N (Cabenuva Spl Graphic 41)

FDA Label Image

Figure O (Cabenuva Spl Graphic 42)

FDA Label Image

Figure P (Cabenuva Spl Graphic 43)

FDA Label Image

Figure Q (Cabenuva Spl Graphic 44)

FDA Label Image

Figure R (Cabenuva Spl Graphic 45)

FDA Label Image

Figure S (Cabenuva Spl Graphic 46)

FDA Label Image

Figure T (Cabenuva Spl Graphic 47)

FDA Label Image

Figure U (Cabenuva Spl Graphic 48)

FDA Label Image

Cabenua 400 mg-600mg Carton (Cabenuva Spl Graphic 49)

Cabenua 400 mg-600mg Carton (Cabenuva Spl Graphic 49)
CABENUVA is a co-packaged, prescription-only injectable suspension for intramuscular use only by healthcare professionals. It contains cabotegravir extended-release and rilpivirine extended-release in the ratio of 400 mg/2 mL with 600 mg/2 mL, respectively. The pack also includes one vial each of cabotegravir and rilpivirine, vial adapters, syringes, injection needles, and syringe labels. The product should be stored at 2°C to 8°C (36°F to 46°F) and not be frozen. Any unused portion should be discarded. For more information about the use of CABENUVA, please refer to the Prescribing Information and Patient Information.*
FDA Label Image

Cabenua 600 mg-900mg Carton (Cabenuva Spl Graphic 50)

Cabenua 600 mg-900mg Carton (Cabenuva Spl Graphic 50)
Cabenuva is an injectable suspension medication packaged with two single-dose vials (cabotegravir extended-release and rilpivirine extended-release), vial adapters, syringes, and injection needles. It is intended for gluteal intramuscular use only, and must be administered by a healthcare professional. The kit contains 600 mg/3 mL of cabotegravir and 900 mg/3 mL of rilpivirine. It should be stored at 2°C to 8°C, and unused portions should be discarded.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.